8-K: Silexion Therapeutics Announces Positive Phase 2 Trial Results for Pancreatic Cancer Treatment

Silexion Therapeutics reports a 56% objective response rate in a Phase 2 trial for its pancreatic cancer treatment, LODER, with a 67% resectability improvement in some patients.

Summary

• Silexion Therapeutics has announced new findings from its Phase 2 trial of LODER for non-resectable locally advanced pancreatic cancer (LAPC).
• The trial focused on patients with the KRAS G12D or G12V mutation, which is present in approximately 70% of pancreatic cancer patients.
• The updated analysis revealed a 56% objective response rate (ORR) in patients treated with LODER.
• The ORR increased to 67% in patients whose tumors became resectable after treatment.
• The company is also developing SIL-204, a next-generation product designed to target a broader range of KRAS mutations with improved stability and delivery.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, indicating a significant step forward in treating a difficult cancer. The development of a next-generation product further enhances the positive outlook.

Positives

• LODER demonstrated a significant 56% objective response rate in patients with non-resectable pancreatic cancer.
• LODER increased the resectability of tumors, with a 67% ORR in patients whose tumors became resectable.
• The company is developing SIL-204, a next-generation product with improved properties and a broader target range of KRAS mutations.
• Previous data showed a 9.3-month improvement in overall survival (OS) with LODER in combination with standard-of-care chemotherapy compared to chemotherapy alone.

Risks

• The company's future success depends on the regulatory environment and compliance.
• There are risks associated with future partnerships or other relationships with third parties.
• The company's future capital requirements and ability to obtain additional capital are uncertain.
• The company's forward-looking statements are subject to risks, uncertainties, and assumptions, and actual results may differ materially.

Future Outlook

Silexion is progressing with the development of SIL-204 and continues to advance its broader pipeline to address KRAS-driven cancers. The company remains committed to pushing the boundaries of therapeutic innovation in oncology.

Management Comments

• We are very encouraged by these new findings, which demonstrate LODER's ability to significantly improve tumor resectability in patients with non-resectable pancreatic cancer, and the improved profile of SIL-204, said Ilan Hadar, Chairman and CEO of Silexion.
• As we advance our broader pipeline to address KRAS-driven cancers, this data further validates our oncogene silencing approach.

Industry Context

This announcement is significant in the context of the broader oncology field, particularly in the development of targeted therapies for KRAS-driven cancers, which are notoriously difficult to treat. The results position Silexion as a potential leader in this area.

Comparison to Industry Standards

• The 56% objective response rate (ORR) and 67% resectability improvement are notable compared to standard treatments for non-resectable pancreatic cancer, which often have lower response rates.
• While specific competitor data is not provided in the document, these results suggest a potential advantage over existing therapies, particularly in the context of KRAS-mutated pancreatic cancer.
• Companies like Mirati Therapeutics and Amgen are also developing KRAS inhibitors, but Silexion's RNAi approach with LODER and SIL-204 offers a different mechanism of action.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with pancreatic cancer may benefit from the potential new treatment options.
• Employees may be motivated by the positive progress of the company's research.

Next Steps

• Silexion will continue to develop SIL-204.
• The company will advance its broader pipeline to address KRAS-driven cancers.

Key Dates

Keywords

pancreatic cancer, LODER, SIL-204, KRAS mutations, RNAi, objective response rate, resectability, oncology, clinical trial, biotech